RLS
ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION Physicians
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Estimated Time to Complete This Educational Activity: 2.0 hours
Methods of participation in this activity can include webcasts, audio-only podcasts, video podcasts, eMonographs or CD-ROM. The post-tests are the same for all delivery methods.
POST-TEST
To take the post-test for Pain & the Sensory Symptoms of RLS you will need to visit The Johns Hopkins University School of Medicine's CME website, If you have already registered for another Hopkins CME program at this site, simply enter the requested information when prompted. Otherwise, complete the registration form to begin the testing process. A passing grade of 70% or higher on the post test/evaluation is required to receive CME credit.
STATEMENT OF RESPONSIBILITY
The Johns Hopkins University School of Medicine takes responsibility for the content, quality and scientific integrity of this CME activity.
Date of release: August 15, 2007 Expiration date: August 14, 2009
TARGET AUDIENCE
This activity has been developed for Physicians. There are no prerequisites
LEARNING OBJECTIVES
At the conclusion of this activity, participants should be able to:
Identify current information related to the diagnosis of Restless Legs Syndrome
Discuss how new treatment methodologies may impact clinical paradigms
Evaluate how the information presented may best be incorporated into current clinical practice
INTERNET CME POLICY
The Office of Continuing Medical Education at The Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. The Johns Hopkins University maintains its Internet site as an information resource and service for physicians, other health professionals and the public.
The Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CE Internet based program. Your information will never be given to anyone outside The Johns Hopkins University program. CE collects only the information necessary to provide you with the service you request.
FACULTY DISCLOSURE
It is the policy of The Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The presenting faculty reported the following:
Richard P. Allen, PhD has disclosed that he has received grant support and honoraria from the NIH and has been a consultant for GlaxoSmithKline, Boehringer Ingelheim, XenoPort, Respironics, and Schwarz Pharma. He has also received grant support and honoraria from IM Systems and is a stock shareholder.
Off-Label Product Discussion
Has indicated that his presentation will include off-label information on gabapentin and opiates used in RLS.
Wayne Hening, MD, PhD has disclosed that he has received grant/research support from GlaxoSmithKline, served as a consultant for Boehringer Ingelheim and Schwarz Pharma, and has been on the Speaker Bureau for Boehringer Ingelheim.
Off-Label Product Discussion
All drugs useful for RLS except dopamine agonists pramipexole and ropinirole are used off label - this includes anti-convulsants used for RLS
Claudia Trenkwalder, MD has disclosed that she has served as a consultant to and has received honoraria from Schwarz Pharma, Boehringer Ingelheim, GlaxoSmithKline, Cephalon, and has received honoraria from Pfizer.
Off-Label Product Discussion
Opioids (tilidine, tramadolol) will be discussed as therapy for RLS as well as
gabapentin.
Christopher J. Earley, MD, PhD has disclosed that he has received grant support from the NIH and received honoraria from GlaxoSmithKline and Boehringer Ingelheim.
Off-Label Product Discussion
Has indicated that his presentation will not include information on off-label products.
Clete Kushida, MD, PhD, RPSGT has disclosed that he has received grant/research support from XenoPort, Inc.
Off-Label Product Discussion
Has indicated that his presentation will include information on XP13512, gabapentin, carbamazepine, valproate, slow-release valproic acid, levetiracetam, lamotragine and zonisamide.
DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.